- Diseases
- Acoustic Neuroma (14)
- Adrenal Gland Tumor (24)
- Anal Cancer (68)
- Anemia (2)
- Appendix Cancer (16)
- Bile Duct Cancer (26)
- Bladder Cancer (68)
- Brain Metastases (28)
- Brain Tumor (230)
- Breast Cancer (720)
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (2)
- Cancer of Unknown Primary (4)
- Carcinoid Tumor (8)
- Cervical Cancer (156)
- Colon Cancer (164)
- Colorectal Cancer (112)
- Endocrine Tumor (4)
- Esophageal Cancer (42)
- Eye Cancer (36)
- Fallopian Tube Cancer (8)
- Germ Cell Tumor (4)
- Gestational Trophoblastic Disease (2)
- Head and Neck Cancer (8)
- Kidney Cancer (126)
- Leukemia (344)
- Liver Cancer (50)
- Lung Cancer (286)
- Lymphoma (284)
- Mesothelioma (14)
- Metastasis (30)
- Multiple Myeloma (98)
- Myelodysplastic Syndrome (60)
- Myeloproliferative Neoplasm (4)
- Neuroendocrine Tumors (16)
- Oral Cancer (100)
- Ovarian Cancer (172)
- Pancreatic Cancer (164)
- Parathyroid Disease (2)
- Penile Cancer (14)
- Pituitary Tumor (6)
- Prostate Cancer (144)
- Rectal Cancer (58)
- Renal Medullary Carcinoma (6)
- Salivary Gland Cancer (14)
- Sarcoma (236)
- Skin Cancer (296)
- Skull Base Tumors (56)
- Spinal Tumor (12)
- Stomach Cancer (60)
- Testicular Cancer (28)
- Throat Cancer (90)
- Thymoma (6)
- Thyroid Cancer (96)
- Tonsil Cancer (30)
- Uterine Cancer (80)
- Vaginal Cancer (16)
- Vulvar Cancer (20)
- Cancer Topic
- Adolescent and Young Adult Cancer Issues (20)
- Advance Care Planning (10)
- Biostatistics (2)
- Blood Donation (18)
- Bone Health (8)
- COVID-19 (362)
- Cancer Recurrence (120)
- Childhood Cancer Issues (120)
- Clinical Trials (632)
- Complementary Integrative Medicine (24)
- Cytogenetics (2)
- DNA Methylation (4)
- Diagnosis (230)
- Epigenetics (6)
- Fertility (62)
- Follow-up Guidelines (2)
- Health Disparities (14)
- Hereditary Cancer Syndromes (124)
- Immunology (18)
- Li-Fraumeni Syndrome (8)
- Mental Health (118)
- Molecular Diagnostics (8)
- Pain Management (62)
- Palliative Care (8)
- Pathology (10)
- Physical Therapy (18)
- Pregnancy (18)
- Prevention (908)
- Research (396)
- Second Opinion (74)
- Sexuality (16)
- Side Effects (606)
- Sleep Disorders (10)
- Stem Cell Transplantation Cellular Therapy (216)
- Support (402)
- Survivorship (322)
- Symptoms (184)
- Treatment (1784)
MD Anderson receives top Chinese science and technology award
BY Ron Gilmore
2 minute read | Published February 11, 2015
Medically Reviewed | Last reviewed by an MD Anderson Cancer Center medical professional on February 11, 2015
MD Anderson was presented the People’s Republic of China International Science and Technology Cooperation Award last month at a ceremony at Beijing’s Great Hall of the People.
The event, attended by Chinese President Xi Jinping, Premier Li Keqiang, and Vice Premier Liu Yandong, recognized MD Anderson’s many international ties to sister institutions in China with which it shares collaborative programs in training, education and patient care. The award is granted through the Chinese State Council to foreign scientists, science and technology engineers and managers, or organizations that have “made important contributions to China’s bilateral or multilateral scientific and technological cooperation.”
Oliver Bogler, Ph.D., senior vice president for academic affairs, accepted the award on behalf of MD Anderson. Ta-Jen Liu, Ph.D., project director of global academic programs, also attended the ceremony.
“Cancer is a significant challenge worldwide,” said Bogler. “Every country has a unique spectrum of cancers, influenced by factors such as population and environment, and collaborating to study these cancers is critical to making progress. China in particular offers tremendous opportunities for saving lives through joint cancer research with top scientists and the government’s commitment to fighting cancer.”
Bogler added that collaborations with Chinese partners have been productive in areas such as cancer screening, liver and lung cancer treatment, and cooperation in clinical trials and basic research studies.
“It is increasingly important to share information and create ties that help all nations in our collective fight against cancer,” said Ron DePinho, M.D., president of MD Anderson. “Receiving this coveted award from China is an honor for our institution and one that speaks to our commitment to collaboration, here at home and across the globe.”
MD Anderson was nominated for the award by its sister institution, Sun Yat-sen University Cancer Center in Guangzhou. Other MD Anderson sister institutions include the Chinese Academy of Medical Sciences Cancer Institute and Hospital in Beijing, Tianjin Medical University Cancer Institute and Hospital, Fudan University Shanghai Cancer Center and the Sir YK Pao Centre for Cancer at Chinese University of Hong Kong.
